KEY DETAILS
Three more personal injury lawsuits over GLP-1 drugs from Novo Nordisk and Lilly were filed in federal court in Pennsylvania in late August. They are early cases with no rulings.
Eli Lilly is testing orforglipron in 2,000 overweight adults to see if it can prevent diabetes and obesity progression.
A 210-person trial in China starting October 2026 will test how well adults with obesity tolerate switching from semaglutide to zovaglutide.
Three more personal injury lawsuits over GLP-1 drugs from Novo Nordisk and Eli Lilly were filed in federal court in Pennsylvania in late August, while two experimental drugs are in trials that could add options in the years ahead. For patients using Ozempic or similar medications, the cases are early and have no rulings. Meanwhile, trials testing orforglipron and zovaglutide suggest that weight loss and diabetes treatment options may keep expanding.
The three cases are Thompson v. Novo Nordisk, filed August 27, and Fernandez v. Eli Lilly and Adkins v. Novo Nordisk, both filed August 28, all in the U.S. District Court for the Eastern District of Pennsylvania. Each is listed as a personal injury product liability case, the kind of claim brought by people who say a drug harmed them. A lawsuit is an allegation, not a finding. These are early cases with no rulings, so nothing about current prescribing or labeling has changed, but patients may want to watch how they develop.
Eli Lilly is also running a large Phase 3 trial of orforglipron, a GLP-1-like drug being tested in 2,000 adults who carry excess weight but have not yet developed diabetes or class 1 obesity. The goal of this study is to see whether the drug can stop that progression before it starts, rather than treating diabetes or obesity after they have already developed. This kind of prevention-focused research differs from most GLP-1 trials to date, which have mainly tested drugs in patients who already have a diagnosis. The trial is currently recruiting, so results are still years away, but the design points to where GLP-1 research may be headed next.
A newer entrant, zovaglutide, from Beijing QL Biopharmaceutical, is set to begin a 210-person trial in China in October 2026. Everyone in the study starts on semaglutide, and then some switch to zovaglutide while others stay on semaglutide. The main goal is to test how well adults with obesity tolerate the switch, measuring side effects rather than which drug works better. Semaglutide, the active ingredient in Ozempic and Wegovy, has become the benchmark that newer GLP-1 candidates are measured against. If zovaglutide is well tolerated, it could eventually give patients and prescribers another option in a market still dominated by a small number of established drugs. The trial has not yet started recruiting, so any comparison remains speculative until results come in.
For patients currently using Ozempic, Wegovy, Mounjaro, or Zepbound, none of these lawsuits have changed what is approved or how these drugs should be prescribed today. I would suggest keeping an eye on the lawsuits as they move forward, keeping in mind that a lawsuit is an allegation until a court rules. At the same time, the arrival of orforglipron and zovaglutide in active trials is a reminder that today's GLP-1 options will likely look different in a few years. Readers weighing a decision now may want to discuss with their doctor whether waiting for new data makes sense for their situation, or whether moving ahead with an approved option fits their needs better.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.